Wellness & Personal Care

What's Happening in Wellness & Personal Care

Obesity drugs have become the dominant growth engine for pharmaceutical valuations, with Eli Lilly raising full-year guidance on accelerating Zepbound and Mounjaro sales while analysts lifted price targets citing sustained momentum in a market where pricing power and margins remain intact against limited near-term competition. Novo Nordisk's experimental amylin-based injection achieved 25 percent weight reduction in women, and its oral obesity pill demonstrated comparable efficacy to injections in real-world use, signaling that both companies are layering multiple mechanisms and delivery formats to capture expanding addressable markets as obesity treatment adoption widens. Lilly and Novo are now pursuing next-generation amylin therapies to extend their reach beyond GLP-1 agonists, while Lilly's dual-drug combination showed stronger weight reduction in Phase 2 testing—a pattern of pipeline deepening that reflects how drugmakers are stacking treatments to defend share as competition intensifies in what has become a high-margin, recurring-revenue category. Separately, Amgen's cancer combination therapy reduced mortality 58 percent in Phase 3 trials, and Moderna's oncology program disappointed in Phase 3 data, creating divergent signals on biotech innovation prospects that affect how investors price pipeline risk across the sector.